Ochre Bio

🚀 Announcing our new multi-year data licence agreement with GSK to investigate the drivers of liver disease! This partnership will provide GSK with access to our advanced computational biology, cellular and perfused human organ platforms to generate proprietary human liver datasets. The data will be used by both GSK and Ochre Bio to build better AI models – allowing for fewer, but more precise, experiments to aid in target choice. The deal has a total value of up to $37.5m for both co-exclusive and non-exclusive data licences. "Data innovation is as important as algorithmic innovation when investing in ML workflows. Both Ochre Bio and GSK share a commitment to providing liver disease patients with more effective medicines and believe in the power of computational modelling to improve therapeutic discovery. These large-scale, causal human datasets will be foundational for our respective liver pipelines." - Jack O'Meara, Co-Founder and CEO. Read our full announcement ➡️ https://lnkd.in/eeETgHV6 #TeamOchre #biotech #genomics #LiverDisease BACKED VC Khosla Ventures Norrsken VC BoxOne Ventures Hoxton Ventures Apollo Ventures Y Combinator LifeLink Ventures Taavet+Sten SSI Strategy Entrepreneur First Pledge Ventures Alexandria Real Estate Equities, Inc.

🩺 Taylor Nielsen's story shows how liver disease can progress as a silent killer. Years of silent damage caught up with the 35-year-old from South Dakota, landing him in a hospital room hoping for a transplant to offer him a second chance. Chronic liver disease is now the leading cause of death for South Dakotans in their 30s, and has the second-highest mortality rates of liver disease and cirrhosis in the US. For Taylor and countless others, the wait for a transplant – which could be between 30 days to over 5 years – can be lethal. Taylor's journey underlines the need for effective treatments that can treat and manage late-stage liver disease without relying solely on transplants. That’s why our mission at Ochre Bio is to develop RNA therapies for chronic liver disease,targeting late stages of disease so there are more options where they're needed most. Read Taylor’s full story in South Dakota News Watch: https://lnkd.in/drE-ZfHa #TeamOchre #Biotech #Genomics #LiverDisease

🚀 We’ve hit the Nasdaq board for a second time this year! This time, we’re spotlighted alongside other venture-backed LGBTQ+ led companies, thanks to our partners at Gaingels. For our founder, Quin Wills, this recognition is especially meaningful as it reflects his personal and professional journey in founding Ochre Bio. We believe diversity is the secret sauce of every high-performing team, and moments like these celebrate our efforts to foster a diverse culture within Ochre. Each of our teams in Oxford, New York, and Taipei brings together unique experiences and perspectives – a strength we believe is crucial for advancing research into complex, late-stage liver diseases and RNA therapies. Learn more about Quin in his Gaingels interview: https://lnkd.in/eHMkVW_y #TeamOchre #Biotech #Genomics #LiverDisease

“The most valuable resource of a company is the people” – Kenny Moore. 👋 Say hello to Kenny, our Head of Research based at our Oxford site. With a Ph.D. in gene therapy from Imperial College London, and over 20 years of experience in molecular biology and RNA research, Kenny has been part of Ochre's journey since 2020, and plays a key role in all aspects of scientific developments – from model development and target discovery to lead optimisation. In his role, he heads up research across our three global sites, overseeing the development of cellular, tissue and organ models to push forward new treatments for chronic liver disease. We asked Kenny about what he enjoys most about his role at Ochre – here’s what he shared 👇 #TeamOchre #Biotech #Genomics #LiverDisease

📊 In 2019 alone, cirrhosis and chronic liver diseases claimed 1.4 million lives – a sharp increase since 1990. Recent research published in BMC Public Health highlights the global burden of chronic liver diseases, which have high mortality rates, particularly in regions with a lower sociodemographic index and among men, who face a 1.5x higher risk of death. Cirrhosis and other chronic liver diseases can catch patients off guard, often progressing silently until the condition is severe and life-threatening. Treatment options for cirrhosis and end-stage liver disease are, unfortunately, still limited: usually liver transplants (with lengthy waiting lists), and very few alternatives. Research like this sheds light on the global scale of liver disease and underscores the urgency of developing therapies for chronic liver disease that end the need for liver transplants. Ochre is developing RNA therapies that target the root of these complex late-stage liver diseases to address this high unmet need. Read the full findings ➡️ https://lnkd.in/eUbrCyyv #TeamOchre #Biotech #Genomics #LiverDisease

Welcoming two new members to the Team Ochre Bio team! 👋 Say hello to Chaehyon (Julia) Lee, our new Research Associate, and Dr. Jan Traulsen, who joins us as a Scientist: 🧬 Julia has brings an MRes in Synthetic Biology from UCL and valuable industry experience in biopharmaceutical process development. Outside the lab, she plays the violin in a symphony orchestra and enjoys getting lost in a good book. 🔬Jan is a molecular biologist with a DPhil in Clinical Medicine, from the University of Oxford, and expertise in infection biology and advanced primary cell models. When he’s not in the lab, you’ll find him spending time with his dogs, cooking or reading. Welcome to Team Ochre, Julia and Jan – we're excited to have you on board! #TeamOchre #Biotech #Genomics #LiverDisease

👁️ Geraldine Frank was looking forward to her 62nd birthday when her son noticed a subtle yellowing in her eyes. What started as a small observation led to a diagnosis of cirrhosis – an advanced liver disease caused by years of silent damage. Nearly 4 in 10 people worldwide have Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a condition that – left undetected – can lead to cirrhosis, end-stage liver disease, or even a spot on the transplant waiting list. In Geraldine’s case, like so many others, the disease progressed quietly until the condition became severe, underlining why new treatments are critical for late-stage disease. At Ochre Bio, we are driven by the urgent need to develop therapies that can make an impact on patients with late-stage liver diseases like cirrhosis. Read Geraldine's story in The New York Times: https://lnkd.in/gvxJdggi #TeamOchre #Biotech #Genomics #LiverDisease

💭 Reflecting on an evening at British Patient Capital x Cooley LLP Our Head of Corporate Development and Business Operations Jack Castle shared some of his top tips for building successful partnerships in the Ochre Bio Deal Spotlight session: 1️⃣ Be clear why you are doing a deal – there should be several compelling reasons! 2️⃣ Find champions at multiple layers of the organisation; scientific champions are critical for early-stage deals 3️⃣ Share a clear R&D plan early on to help partners understand how your unique platform can add value 4️⃣ Discuss the shape of a deal structure before price to align expectations 5️⃣ Keep the momentum going: this is essential for maintaining progress and focus It was also great to hear from Laura A. Lane, Jane Dancer, Roel Bulthuis, and Michel de Baar, PhD, MBA, in a panel focused on structuring deals and determining when to pursue a deal. Thanks to British Patient Capital and Cooley LLP for hosting such an insightful event, and to everyone who joined the conversation! #TeamOchre #Biotech #Genomics #LiverDisease

🧬 Turning complex data into therapies starts with the right tools. This means we focus on: 🔸 Generating a large amount of data to gain an unfair advantage 🔸 Developing translatable human models to really interrogate the biology 🔸 Seeing tractable clinical trial opportunities that we can execute on The liver provides and opportunity for Ochre to do this and optimise our chances of being successful. Curious to learn more? Listen to our CSO and Founder Quin Wills, on the Business of Biotech podcast with Matthew Pillar, to discover how we're reshaping liver disease research and therapy development. 🎧 Spotify: https://lnkd.in/ehP4YV35 🖥️ Youtube: https://lnkd.in/egvtfsXN #TeamOchre #Biotech #Genomics #LiverDisease

Our Founder & CSO Quin Wills will be chairing a panel at this year's BioTechX! Join Quin, Caroline Lustenberger, Kaja Zarakowska, Raghib Ali OBE, James Duboff, as they explore how population genomics is shaping drug R&D – including the successes, as well as where (and why) challenges remain. 📅 09 October, 16:45 CEST 📍 Basel, Switzerland Get in touch with Quin if you’re attending and would like to arrange a meeting! Full programme here: https://lnkd.in/gHvAR2qS #TeamOchre #Biotech #Genomics #LiverDisease